Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:NWPHF
CUSIPN/A
WebN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.17 million
Price / Sales10.87
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares17,840,000
Market Cap$164.88 million
Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions
What is Newron Pharmaceuticals' stock symbol?
Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF."
Who are some of Newron Pharmaceuticals' key competitors?
Some companies that are related to Newron Pharmaceuticals include Abeona Therapeutics (ABEO), Viking Therapeutics (VKTX), CannTrust (CNTTF), GlycoMimetics (GLYC), Adamas Pharmaceuticals (ADMS), Verastem (VSTM), Homology Medicines (FIXX), Urogen Pharma (URGN), Arcus Biosciences (RCUS), Progenics Pharmaceuticals (PGNX), Prothena (PRTA), Insys Therapeutics (INSY), OptiNose (OPTN), AC Immune (ACIU) and Theratechnologies (THERF).
Who are Newron Pharmaceuticals' key executives?
Newron Pharmaceuticals' management team includes the folowing people:
- Mr. Stefan Weber, CEO & Exec. Director (Age 53)
- Mr. Roberto Galli, VP of Fin.
- Mr. Marco Caremi, Exec. VP of Bus. Devel. (Age 61)
- Dr. Ravi Anand M.D., Ph.D., Chief Medical Officer (Age 61)
- Mr. Dennis Dionne, VP of Commercial Affairs (Age 68)
Has Newron Pharmaceuticals been receiving favorable news coverage?
Headlines about NWPHF stock have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Newron Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 46.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Newron Pharmaceuticals.
How do I buy shares of Newron Pharmaceuticals?
Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Newron Pharmaceuticals' stock price today?
One share of NWPHF stock can currently be purchased for approximately $9.2444.
How big of a company is Newron Pharmaceuticals?
Newron Pharmaceuticals has a market capitalization of $164.88 million and generates $15.17 million in revenue each year.
MarketBeat Community Rating for Newron Pharmaceuticals (OTCMKTS NWPHF)
MarketBeat's community ratings are surveys of what our community members think about Newron Pharmaceuticals and other stocks. Vote "Outperform" if you believe NWPHF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWPHF will underperform the S&P 500 over the long term. You may vote once every thirty days.
